摘要
目的比较沙格列汀与二甲双胍治疗初诊伴超重的2型糖尿病患者的疗效。方法选取合并超重的初诊2型糖尿病患者124例,随机分为二甲双胍治疗组(62例)和沙格列汀治疗组(62例),分别在生活方式干预基础上给予常规沙格列汀与二甲双胍治疗,随访12w,检测治疗前后血压、血糖、糖化血红蛋白、血脂、胰岛素等指标,并比较两组的治疗效果。结果两组治疗后血糖均较治疗前明显下降,差异有统计学意义(P<0.05);沙格列汀组空腹血糖与糖化血红蛋白下降程度与二甲双胍组比较,差异无统计学意义(P>0.05),沙格列汀组餐后血糖低于二甲双胍组,差异有统计学意义(P<0.05),两组患者血压、血脂等指标均较治疗前有所好转,但组间差异无统计学意义(P>0.05)。结论对于合并超重的初诊的2型糖尿病患者,沙格列汀和二甲双胍治疗效果相当。
Objective To compare the efficacy of saxagliptin and metformin to newly diagnosed type 2 diabetes with overweight. Methods 124 cases who were newly diagnosed type 2 diabetic patients with overweight were divided into two groups and given saxagliptin and metformin respectively for 12 weeks based on lifestyle intervention. Then compare the treatment effect between two groups based on the detection of Blood pressure, blood glucose, glycated hemoglobin, lipids, insulin and other indicators of everyone before and after treatment. Results Blood glucose were significantly reduced after any kind of drugs treat- ment, and the difference was statistically significant （P〈0.05）;The postprandial blood glucose of Saxa- gliptin group is lower than metformin group （P〈0.05）, while, there was no statistical significance in the comparison between the decrease of fasting blood glucose and glycosylated hemoglobin of Saxagliptin group and metformin group （P〉0.05）; blood pressure, lipids and other indicators were improved com pared with before treatment in two groups , but no significant difference between two groups （P〉0.05） Conclusion For the cases combined overweight with newly diagnosed type 2 diabetes , the effect of saxa gliptin and metformin treatment is equal.
出处
《新疆医科大学学报》
CAS
2014年第4期473-475,共3页
Journal of Xinjiang Medical University
基金
克拉玛依科学技术局技术研发项目(SK2011-34)
